Triple-Negative Breast Cancer (TNBC) Completed Phase 1 Trials for Ipilimumab (DB06186)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01986426LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or PembrolizumabTreatment